Bank of America Corp DE boosted its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) by 27.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,083,689 shares of the company's stock after purchasing an additional 236,459 shares during the period. Bank of America Corp DE owned about 0.18% of Fresenius Medical Care AG & Co. KGaA worth $36,499,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. FDx Advisors Inc. purchased a new position in Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $315,000. Freestone Capital Holdings LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $390,000. Guardian Capital Advisors LP boosted its stake in Fresenius Medical Care AG & Co. KGaA by 10.7% in the first quarter. Guardian Capital Advisors LP now owns 52,148 shares of the company's stock valued at $1,744,000 after acquiring an additional 5,045 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Fresenius Medical Care AG & Co. KGaA by 18.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,706 shares of the company's stock valued at $158,000 after acquiring an additional 730 shares during the last quarter. Finally, Cacti Asset Management LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 35.8% in the first quarter. Cacti Asset Management LLC now owns 36,000 shares of the company's stock valued at $1,212,000 after acquiring an additional 9,500 shares during the last quarter. 5.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on FMS. JPMorgan Chase & Co. dropped their target price on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research note on Monday, August 1st. Berenberg Bank dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a research note on Wednesday, August 10th. DZ Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research note on Friday, July 29th. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and upped their price target for the company from $30.30 to $33.70 in a research note on Monday, June 27th. Finally, UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research note on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $45.83.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.04). Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.70% and a net margin of 4.42%. The firm had revenue of $5.07 billion during the quarter, compared to analysts' expectations of $4.80 billion. Analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.64 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

• Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• Thor Industries Hammers Out A Bottom
• How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.